原研机构 |
非在研机构- |
权益机构- |
最高研发阶段临床1期 |
首次获批日期- |
最高研发阶段(中国)临床1期 |
特殊审评- |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
急性胸部综合征 | 临床1期 | 中国 | 2024-09-02 | |
β地中海贫血 | 临床1期 | 中国 | 2024-04-18 | |
镰状细胞血症 | 临床1期 | 中国 | - |
NEWS 人工标引 | 临床1期 | 1 | 顧醖鏇蓋構壓遞選艱醖(夢願鑰範艱繭餘憲鬱範) = 窪範鏇選餘鑰艱築積醖 鏇觸廠網淵遞鏇築襯餘 (糧積鹹構淵鹹夢簾壓鹽 ) 更多 | 积极 | 2025-08-26 | ||
N/A | 9 | CS-101 | 齋膚襯襯獵願選鏇衊憲(築積襯觸選獵醖鏇夢衊) = All participants had ≥1 adverse event (AE) of Grade 3 or 4 severity (including laboratory-based AEs). The observed adverse events following CS-101 infusion were largely consistent with those typically associated with busulfan myeloablative conditioning. No deaths, discontinuations, or malignancies were reported. 積艱製觸艱蓋憲鹽壓構 (鑰範壓築範願鹹積廠醖 ) | 积极 | 2025-05-14 | ||
临床1期 | 6 | 選襯夢淵醖遞構憲艱膚(襯遞齋鬱觸廠製網蓋齋) = All participants had ≥1 adverse event (AE) of Grade 3 or 4 severity (including laboratory-based AEs). The most three common Grade 3 or 4 AEs were neutrophil count decreased (100%), platelet count decreased (100%), and white blood cell decreased (100%). Most AEs were commonly observed after myeloablative busulfan conditioning and no AEs were reported as related to CS-101 in the 6 patients. 顧製鑰遞構衊繭鹹構鬱 (鑰積淵夢壓憲鏇憲鬱觸 ) 更多 | 积极 | 2024-12-09 | |||
临床1期 | 1 | 淵糧憲網憲願夢憲蓋艱(鹹鏇餘夢糧膚鏇構衊顧) = 齋淵範築鹹構膚夢顧膚 艱繭築觸襯網憲觸築築 (淵憲鏇鏇遞築鬱壓衊選 ) | 积极 | 2024-01-08 |